Long-term culture-initiating cells (LTC-IC) are arguably the most primitive human hematopoietic cells detectable by in vitro functional assays. We have investigated the mobilization of these cells into the blood of patients with ovarian carcinoma randomized to receive granulocyte colony-stimulating factor (G-CSF; 5 pglkg) plus different doses of stem cell factor (SCF; c-kit ligand) after chemotherapy or G-CSF alone after chemotherapy. We have shown a significant SCF dose response for the mobilization of LTC-IC, with a 5.8-fold increase in LTC-IC mobilization in those patients receiving chemotherapy, G-CSF, and 20 pg/kg of SCF, the highest dose used, compared with the patients receiving chemother-HE PRESENCE OF primitive hematopoietic cells in adult peripheral blood (PB) has been recognized for more than 30 years. Initial canine and murine studies in the 1960s showed blood cells capable of protecting recipients from lethal doses of whole body irradiation by restoring blood cell formation from circulating donor cell^."^ Subsequent studies led to detection and quantitation of progenitor cells by colony assays5" and the effects of growth factors on their numbers in the c i r c~l a t i o n .~~~ More recently, this was followed by investigation of the apheresis productLGL4 as an alternative source to bone marrow cells for transplantation after myeloablation. As a result, not only has intensive investigation into PB mobilization regimens been conducted, but also quantitative assays for cells capable of reconstituting and sustaining hematopoiesis in transplant recipients have been perf~rmed.'~"~ Long-term culture-initiating cells (LTC-IC) are arguably the most primitive human hematopoietic cells detectable by in vitro functional assays. They are capable of generating myelopoid and erythropoid progenitor cells (colony-forming unit-granulocyte-macrophage [CFU-GM] and burst-forming unit-erythroid [BFU-E]); in murine transplantation protocols, the assay detects the marrow repopulating cell^.^'^^^ Stem cell factor (SCF), a glycoprotein hematopoietic growth factor, is the ligand for the tyrosine kinase receptor encoded by c-kit." A recent study in primates" has shown the ability of SCF alone to mobilize PB progenitor cells (PBPCs). When used in combination with granulocyte colony-stimulating factor (G-CSF), low doses of SCF have been shown to give enhanced mobilization of PBPCs compared with G-CSF alone. In mice,22 prirnates,z3 and canines,z4 the combination of optimal doses of G-CSF with low-dose SCF (25 pgkg/d) resulted in increased numbers of circulating white blood cells (WBCs) and both mature and primitive progenitor cells. Transplantation of irradiated mice or canines with these PBPCs resulted in enhanced radioprotection and recovery of platelets and WBCs after tran~plantation.'~.~~ Initial clinical studies involving SCF have investigated mobilization of PBPCs using the cytokine alone or in combination with G-CSF but not involving chemotherapy. Early results from these studies have shown increasing mobilization of progenitor cells (granulocyte-macrophage colonyforming cells [GM-CFC] and BFU-E) and CD34+ cells with 
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MATERIALS AND METHODS
Previously untreated patients between 16 and 65 years of age with histologically proven epithelial ovarian cancer (International Federation of Gynaecology and Obstetrics [FIGO] stages IC to IV) were investigated.26
All patients (N = 48) were treated with 3 g/m2 cyclophosphamide administered as a 4-hour intravenous infusion and 6 g/m2 mesna as a 12-hour infusion on day 1. The patients were randomized to receive 5 pgkg recombinant human G-CSF (filgrastim; Amgen, Thousand Oaks, CA) alone or together with recombinant human SCF (Amgen). The dose of SCF was cohort dependent, with 12 patients in each cohort, 9 of whom received SCF plus G-CSF (5 pgkg); the remaining 3 patients received G-CSF (5 pgkg) alone. The dose of SCF was 5, 10, 15, and 20 pgkg in cohorts 1, 2, 3, and 4, respectively. Growth factors were administered daily, starting 48 hours after chemotherapy, until the PB WBC count was 24 X 109/L, when all patients underwent a single apheresis. The clinical data and the use of the apheresis product will be reported separately. Patients were subsequently treated with a dose-intensive protocol consisting of carboplatin (AUC 7.5) and 900 mg/m2 cyclophoshpamide delivered every 3 weeks. A total of 4 cycles of this combination chemotherapy were administered, with each cycle to be followed by the reinfusion of one fourth of the apheresis product.
Patients at the Christie Hospital (N = 37) had PBPCs collected on a Spectra cell separator (Cobe Laboratories, Lakewood, CO) using a continuous collection procedure until 2.5 x the patient's blood volume had been processed. Patients at Nottingham (N = 6) and Newcastle (N = 5) had their cells collected on a Baxter CS 3000 cell separator (Baxter Fenwal Division, Deerfield, IL), and a similar volume of blood was processed.
To investigate the LTC-ICs, the murine bone marrow stromal cell line M2-10B4 was used as a supporting layer. A single-cell suspension of M2-10B4 stromal cells in RPMI-I640 medium (GIBCO, Grand Island, NY) and 10% fetal calf serum was plated at a final concentration of 1 X lo4 cells/well into the inner wells of 96-well tissue culture plates (Falcon; Becton D i c k " , Meylan, France) and incubated at 33°C for 48 hours, by which time the stromal layers became approximately 70% confluent. The plates were then irradiated (80 Gy; 8 MeV electrons delivered via a linear accelerator) to halt further proliferation and were then ready to receive test inocula.
The test inocula from an aliquot of the apheresis product were processed in a ficoll density gradient (1.077 g/cm2). The low-density cells were removed and washed in 1% bovine albumin serum in phosphate-buffered saline solution, and the adherent cells were subsequently removed by overnight incubation in plastic flasks containing 2 X IO6 cells/mL of Iscove's modified Dulbecco's medium (IMDM; GIBCO) supplemented with 15% fetal calf serum at 37°C and 5% C 0 2 and 5% 02. For each experiment, four dilutions were used, with 30 replicate wells for each dilution. Cells were plated at concentrations ranging from 2.5 x 10' to 7.5 X lo4 mononuclear cells (MNCs)/mL. The dilutions were chosen to be maximally informative at weeks 5 to 6 of the assay, aiming to yield 10% to 37% of the wells negative for cobblestone areas. Each culture was fed every 7 to IO days. After 5 weeks of incubation, wells were scored positive if cobblestone areas consisted of 15 or more small, polygonal, tightly packed cells that were nonrefractory (dark) when viewed under a phase contrast microscope."."
Fifty microliters of blood or apheresis product was labeled with anti-CD34, phycoerythrin (PE)-conjugated monoclonal antibody (MoAb; anti-HPCA-2; Becton Dickinson, Mountain View, CA) and its isotype-matched control was always performed at the same time. Cells were incubated at room temperature for 15 minutes. The red blood cells were then lysed (Ortho-mune lysing reagent; Ortho Diagnostic Systems, Raritan, NJ) and washed in phosphate-buffered saline. Cells were analyzed by fluorescence-activated cell sorting (FACScan; Becton Dickinson). For each sample, a minimum of 50,000 cells was analyzed.2x CD34 subset analysis was also performed on the apheresis product. Fifty microliters of apheresis product was labeled with anti-CD34, fluorescein isothiocyanate (F1TC)-conjugated MoAb (anti-HPCA-2; Becton Dickinson), anti-CD33, and PE-conjugated MoAb (Leu M9; Becton Dickinson) and its isotype-matched controls were always performed at the same time. A separate aliquot of apheresis product was labeled with anti-CD34, FITC-conjugated MoAb (anti-HPCA-2; Becton Dickinson), anti-CD38, PE-conjugated MoAb (Leu 17; Becton Dickinson) and its isotype-matched control was always performed at the same time. These samples were then processed as described above, ie, the red blood cells were lysed and the sample was then washed. Analysis was performed by gating the lymphocytekdast population on forward-angle light scatter followed by the test statistics being performed on the plot of CD33 or CD38 LTC-IC assays.
CD34 analysis.
fluorescence against CD34 fluorescence. It is important to state that, for these CD34 subset analyses, a minimum of 500,000 cells was processed.
Estimates of LTC-IC frequencies were initially analyzed by standard limiting-dilution assay technique^.'^ Each well was scored as positive or negative, with the following two assumptions being made. (I) There was a random suspension of LTC-ICs in each dilution. (2) If an LTC-IC was present in the test inoculum for a particular well, it would result in a positive response, ie, singlehit model. If we let i index the individual patient and j index the dilution within the patient, with the two above-mentioned assumptions, the following model should hold: rtJ follows a binomial distribution (nu,-
where r is the number of positive wells of n, p is the probability of a well being positive, X is the number of cells overlaid, and p is the log frequency of LTCICs (natural logarithm). This is a generalized linear model and we may estimate the 0's using the method of maximum likelihood as implemented in generalized linear interactive modelling (GLIM). This model is appropriate for obtaining estimates of individual stem cell frequencies along with their standard errors. To address the differences between the cohorts, ie, changes in LTC-IC frequency with increasing dose of SCF, a model incorporating effects representing mean frequencies of stem cells in each group along with a random effect term representing variability in frequencies across individuals within a group is suitable.
If i denotes the individual patient as before, j the dilution within the patient, and k denotes the treatment group (ie, cohorts 1 through 4), a new model may be written as follows: rl, follows a binomial distribution (ni,,p,) with In[-ln(l -P,~)] = Inx, + Pk + yz,, where r, n, p, and X are as before, but the four ps now represent the mean log frequencies of LTC-IC in each group and the z's are unobserved independent standard normal random variables. Under this model, the log frequencies of inhviduals within a group are assumed to follow a normal distribution with the mean equal to the group mean Pk and standard deviation y . This model and other similar ones may be fitted using an expectation-maximization (E-M) algorithm along the lines of Anderson and Aitkin."
Three models are of interest.
(1) A model outlined as above allowing separate means for each group. (2) A model with a single common mean. (3) A model with a linear trend in the mean log frequencies with an escalating dose of SCF (0, 5, 10, 15, and 20 pg/kg/d). These three statistical models were compared using likelihood ratio tests. Figure 1A and Table 1 show that there was an increasing and statistically significant trend in median CD34+ cells obtained in the apheresis product of patients as the dose of SCF was increased ( P < Likewise, when CD34 subsets were analyzed, it was found that the median numbers of CD34+/33-cells per kilogram of body weight increased in an SCF dose-dependent fashion (Fig 1B and Table 1) . Interestingly, the effect on mobilization of CD34+/33-populations did not reach a plateau at 15 mgkg but continued to increase, at least to the 20 pg/kg dose of SCF used in this trial. A very different result was seen when CD34+/38-subsets were studied. Despite 500,000 cells being analyzed for each sample, significant levels of CD34+/38-cells could only be detected in the Next, the three models incorporating group means and a random effect were fitted to assess if the increasing dose of SCF between the groups was having an effect on LTC-IC frequency. The primary hypothesis of no dose-related effect was firmly rejected by comparing the model allowing separate means for each group with the model using a single common mean (model 1 compared with model 2). There was a highly significant effect of SCF dose influencing the frequency of LTC-IC mobilization ( P = ,00003). This is shown by the median frequencies and their ranges as shown in Table 2 . As the dose of SCF is increased, the median frequency of LTC-IC in the MNC fraction of the apheresis product increases from 1:10,916 cells for the chemotherapy plus G-CSF alone group up to 1:2,540 cells in the chemotherapy plus 20 pg/kg SCF i-G-CSF cohort. Data in the cohort receiving G-CSF plus 5 pg/kg SCF after chemotherapy are not available. Figure 2 shows the plot of all individual estimates of the log frequencies. Superimposed on the plot are the estimated group means from the models incorporating the random effect term. The divergence of the mean log LTC-IC frequency for each cohort (solid lines) and the mean estimated from the linear trend model (dashed lines) at the higher doses of SCF may suggest a plateauing in the mobilization of LTC-IC, although this effect is not sufficient to contradict the presence of a linear trend ( P = .17).
Statistics.

RESULTS
Another important observation was that the range of LTC-IC frequencies in patients mobilized in the G-CSF alone cohort was larger than that seen in any of the cohorts of patients who had received SCF as part of their mobilization regimen (Table 2 and Fig 2) . The range of LTC-IC frequencies within a cohort appeared to reduce as the dose of SCF was increased, with a similar tailing off of the effect between the 15 and 20 pg/kg cohorts.
The estimated magnitude of effect on LTC-IC mobilization is a 4.3-fold increase in their median frequency induced by chemotherapy plus 20 pg/kg SCF + 5 pg/kg G-CSF over that produced by chemotherapy plus G-CSF alone from the separate means model ( P = .00003) and an equally significant result ( P < ,00003) of a 5.8-fold increase from the linear trend model.
The vast majority of patients tolerated the growth factor injections with either mild or no adverse events. The most common side effect in patients receiving filgrastim alone was musculo-skeletal pain at the time of neutrophil recovery from the nadir after 3 g/m2 cyclophosphamide. This occurred in 3 of 12 patients. In the SCFtreated patients, musculo-skeletal pain occurred at a similar time of neutrophil recovery as the in the patients treated with filgrastim alone. However, this adverse event occurred more frequently, with 17 of 36 SCF-treated patients being affected. The most common adverse event due to SCF was a local Toxicity. skin reaction at the injection site. These reactions consisted of mild oedema surrounded by a ring of erythema. This type of skin reaction occurred in 27 of the 36 patients receiving SCF, started approximately 4 hours after the SCF injection, and lasted for between 24 and 48 hours, after which it resolved completely. No patient suffered any skin reactions distant to the injection site apart from the 1 patient who developed an anaphylactoid-type reaction after her first injection of SCF at 20 pgkg. This patient required intravenous chlorpheniramine, hydrocortisone, and intramuscular adrenaline to relieve the urticaria, chest tightness, and mild stridor resulting from laryngeal oedema. She made a full recovery, but, as a consequence of this reaction, was withdrawn from the study. A second patient in the 20 pgkg SCF group was withdrawn from the study because it was impossible to obtain adequate venous access to perform the apheresis harvest.
DISCUSSION
This is the first study to investigate the effects on mobilization of LTC-IC by the administration of SCF in a clinical setting. It is also the first study to report on the effects of SCF administered in combination with G-CSF after chemotherapy. To our knowledge, these are also the first published data on the frequency of LTC-ICs mobilized into the blood using an increasing dose of hematopoietic growth factor.
We have shown that the number of CD34+ cells and CD34'/33-cells mobilized increases in a dose-dependent fashion according to the dose of SCF administered. However, despite large numbers of cells being analyzed (500,000), it was only the final cohort of patients (20 pgkg SCF) who had significantly detectable levels of CD34+/38-cells. It has been suggested that the most primitive hematopoietic cells lie within the CD34+/38-population.7'.32 Because the LTC-ICs are found to increase in a dose-dependent fashion after the administration of SCF, it may be that the biologic LTC-IC assay is, under the conditions used, more sensitive than immunotyping for assessing the frequency of "stem cells" mobilized. Until a more clearly defined phenotype associated with "stem cells" is established, it remains prudent to perform functional assays when investigating primitive cells in addition to phenotyping analysis. A similar conclusion was drawn from studies on steady state PBPCs by the Vancouver group. 33 We have shown that, as the dose of SCF is increased, there is a significant increase in the mobilization of LTC-IC. The magnitude of the mobilization of LTC-IC with chemotherapy and the highest dose of SCF plus G-CSF was marked in comparison with the effect of chemotherapy plus G-CSF alone (5.8-fold increase). The magnitude of the increase was very similar to the fivefold increase in the numbers of both GM-CFC and BFU-E colonies and the threefold increase in CD34+ cells in the apheresis product of patients receiving 20 pgkg SCF plus G-CSF after chemotherapy, as compared with those receiving G-CSF alone after chemotherapy.26 This relative increase in LTC-ICs in comparison to the progenitor cell mobilization is very large compared with a previous report by Sutherland et al.74 They showed a much lower fold increase over baseline values in LTC-ICs after cyclophosphamide chemotherapy with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) compared with the fold increase in progenitor cells over baseline steady state levels (5.6-fold v 26-fold increase, respectively). They concluded that LTC-ICs can be mobilized into the blood by the treatments used to transiently increase numbers of colony-forming cells in the circulation, but to a more limited extent. However, our results suggest that SCF in combination with G-CSF is equally effective acting on the more primitive cell population as on the progenitor cells in inducing their mobilization into the PB.
The definition of an adequate harvest remains uncertain. A number of studies have suggested that the total MNC count, the weight-adjusted MNC count, or the number of CFU-GM or CD34' cells is able to predict for hematopoietic r e c~v e r y .~' ,~~ It is clear from our study that even the patients who had blood cells mobilized using chemotherapy and G-CSF alone, in whom the median number of CFU-GM observed was 12.4 X lO5/kgZ6 and the CD34' cells count was 3.2 X lO%g (Table I) , far exceeded the majority of investigators' threshold target for an adequate number of CD34' cells or CFLJ-GM (2 x lO%g and 2 X 105kg, respecti~ely).~' Once the threshold number of cells has been reinfused, there appears to be little advantage in reinfusing cell numbers over and above this level to reconstitute a patient hematologically (reviewed in Bender et Consequently, the hematopoietic reconstitution data from the patients studied here may not be the most informative clinical parameter by which to assess the relevance of the increased numbers of LTC-ICs found in this study. In addition, the contribution of clonogenic cells versus LTC-ICs to early and late phases of engraftment remains essentially unknown. The Vancouver For personal use only. on November 11, 2017. by guest www.bloodjournal.org From group was unable to show any significant correlation between the speed of engraftment and the progenitor cell/LTC-IC content in a series of 21 patients with various malignancies. 34 An alternative, clinically relevant exercise may be to calculate the volume of blood required to be processed had a target number of 2 x lo4 LTC-ICkg been specified for an adequate collection, based on the number of cells accepted for allogeneic transplantation and the measured incidence of LTC-ICs in normal bone marrow and in selected CD34+ cell^.'^^^^ The patients treated here with G-CSF alone after chemotherapy would have required approximately a median of 3.2 L of blood to be processed to obtain such a target, whereas those patients receiving 20 pgikg SCF with G-CSF after chemotherapy would only require 0.83 L of blood to be processed. Likewise, to obtain 2 X 106kg CD34+ cells would require a median 5 L of blood to be processed in those patients treated with G-CSF alone after chemotherapy, and only a median of 1.58 L of blood would have to be processed in those treated with 20 p g k g SCF plus G-CSF after chemotherapy.
It has been shown that there is marked variability (up to 100-fold) in the response to mobilization stimulus between patient^.^^.^' Peters et a13' showed considerable interpatient variation in mobilization and large variations between individual days of collections for any given patient when they were mobilized using G-CSF or GM-CSF. 36 We have shown that, as the dose of SCF is increased, it tends to reduce the variability of observations within each cohort, with the most significant difference in variability being between the patients in the G-CSF alone cohort compared with those patients receiving SCF at 15 or 20 pgikg (Fig 2) . This may have important implications for patients who unpredictably mobilize primitive cells into the PB relatively poorly, because these patients may well have their LTC-IC/progenitor cell yields increased by the addition of SCF to their mobilization regimen.
The methodology for the LTC-IC assay has to be carefully defined. When the assay was first described, the endpoint measured was the ability to give rise to clonogenic cells after at least 5 weeks of culture on pre-established bone marrow ~t r o m a . '~ More recently, Breems et all7 described an altemative endpoint using cobblestone area formation. We have previously compared endpoints (cobblestone v colony forming cell generation) in LTC-IC assays using normal bone marrow as the supporting stroma. This comparison showed equivalence between the two endpoint^.'^ We have more recently also determined the frequencies of LTC-IC using different supporting stromal layers (M2-10B4 v normal bone
The numbers of cobblestone areas on the M2-10B4 cell line was 3.21 times higher compared with those (produced by the same test inocula) on normal bone marrow. This suggests that, had the experiments presented here been performed on supporting layers of normal bone marrow, the absolute frequencies of LTC-IC would have been approximately one third of that indicated by the results obtained using the M2-10B4 cell line stroma. However, this would not alter the 5.8-fold increase in mobilization of LTC-ICs between the 20 pgkg SCF cohort and the G-CSF alone cohort (Table 2 ). In summary, we have shown a highly significant, SCF dose-dependent increase in the mobilization of LTC-IC by the use of chemotherapy plus SCF and G-CSF compared with that produced by chemotherapy and G-CSF alone. We have also shown significant differences between the functional LTC-IC assay and the phenotyping of subpopulations of CD34+ cells, suggesting that, when investigating stem cell frequencies, one should not entirely rely on phenotyping of cells as the sole method of investigation, but rather functional assays should remain an important research method when new protocols are developed.
Lastly, and importantly, it appears that SCF decreases the variability of LTC-IC mobilization between individuals. If this were reproduced in other clinical settings, SCF may provide a possible means of standardizing and improving mobilization of these primitive hematopoietic cells.
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